Loading...
| A04004 | Pages: 289 | Jun 2020 | 11813 Views | | |
| Author(s) : Sanjivan Gill , Onkar Sumant | Tables: 86 | Charts: 87 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Europe In Vitro Diagnostics Market
Request Now !The Europe in vitro diagnostics market (IVD) was valued at $13,825 million in 2019, and is projected to reach $18,647 million at a CAGR of 4.8% from 2020 to 2027.
In vitro diagnostics (IVD) include medical devices, assays and reagents, which are employed in diagnosis of a medical condition. Furthermore, these instruments are employed in analysis of tissue samples and body fluids collected from a patient. Moreover, there are various types of in vitro diagnostic instruments that work on different techniques such as immunodiagnostics, tissue diagnostics, hematology, and molecular diagnostics. Furthermore, in vitro diagnostics are employed in diagnosis of various medical conditions such as infectious diseases, cancer, cardiac disorders, and nephrological disorders. Moreover, use and handling of in vitro diagnostics require technical expertise and thus, instruments are used in specialized medical facilities to carry out diagnosis. For instance, IVD products are used in facilities such as standalone laboratories, hospitals, and point-of care.
Get more information on this report : Request Sample Pages
The major factor that contributes to the growth of the Europe in vitro diagnostic market is surge in number of in vitro diagnostic tests, which is attributable to rise in incidences of chronic and infectious diseases. Furthermore, growth in geriatric population, which is prone to immunological disorders is another major factor that boosts the growth of the market. Moreover, rise in use of personalized medicines in treatment of various chronic diseases such as cancer also fuels growth of the Europe in vitro diagnostics market. In addition, increase in technological advancements associated with in vitro diagnostic products, technologies, and software & services boosts the market growth. However, stringent government regulations and unfavorable reimbursement policies are anticipated to restrict growth of the Europe in vitro diagnostics market. On the contrary, potential for outsourcing present lucrative opportunities for key players in the Europe in vitro diagnostics market during the forecast period.
Europe observed social distancing through nationwide lockdowns during the COVID-19 pandemic. This lead diverse changes in every industry such as new challenges in supply chains, rising and falling demands of products, availability of resources and others. Similarly, in vitro diagnostics market in Europe was also affected by the COVID-19 outbreak. In addition, the impact was either positive or negative for different sectors of in vitro diagnostics industry. For instance, the impact of nationwide lockdowns in Europe was not favorable for the some of the in vitro diagnostic services. However, the sudden demand for new IVD products for COVID-19 testing resulted in key players launching various type of test kits. Therefore, the new test kits were granted Conformité Européene (CE) Mark in Europe which ensured the availability of safe the test kits.
The report segments the market into product & service, technique, application, end user, and region. On the basis of product & service, the market is segmented into chemicals & reagents, instruments, and services & software. On the basis of technique, it is categorized into immunodiagnostics, hematology, molecular diagnostics, tissue diagnostics, clinical chemistry, and others. In addition, the immunodiagnostics segment is further divided into enzyme-linked immunosorbent assay (ELISA), rapid tests, enzyme-linked immunospot (ELISPOT), radioimmunoassay (RIA), and western blot. Moreover, the ELISA segment is further divided into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA), and colorimetric immunoassay (CI). Similarly, the molecular diagnostics segment is divided into polymerize chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), hybridization, DNA diagnostics, microarray, and others.
The clinical chemistry segment is further divided into basic metabolic panel, liver panel, lipid profile, thyroid function panel, electrolyte panel, specialty chemicals, and others.
On the basis of application, the market is segmented into infectious diseases, cancer, cardiac diseases, immune system disorders, nephrological diseases, gastrointestinal diseases, and others. On the basis of end user, it is categorized into standalone laboratories, hospitals, academics & medical schools, point-of-care, and others. Country wise, the market is analyzed across Germany, France, the UK, Italy, Spain, and rest of Europe.
On the basis of product & service, the chemicals & reagents segment acquired major share in 2019. The growth of the segment is attributed to the fact that chemicals & reagents are a vital part of every in vitro diagnostic test. Hence, the aforementioned factors contribute to the growth of this segment. In addition, the instruments segment is expected to grow at the fastest CAGR during the forecast period, owing to rise in focus of key players toward launching of new instruments.
Get more information on this report : Request Sample Pages
By application, the infectious diseases segment has the highest potential, owing to increase in incidences of HIV-AIDS, hepatitis, and other infectious diseases.
Get more information on this report : Request Sample Pages
Germany is expected to be the leader in the Europe in vitro diagnostics market during the forecast period, owing to surge in prevalence of infectious diseases, which lead to rise in use of immunodiagnostics used in infectious disease diagnostics. In addition, other factors such as rise in use of rapid tests such as continuous glucose monitoring and flash glucose monitoring also contribute to the growth of the Germany in vitro diagnostics market. Moreover, the UK is expected to register the highest growth rate during the forecast period, owing to rise in incidences of seasonal flu, leading to rise in use of point-of-care testing. In addition, rise in awareness related to use of in vitro diagnostics is another major factor that contributes to the growth of the Europe in vitro diagnostics market.
Get more information on this report : Request Sample Pages
The Europe in vitro diagnostics market is highly competitive and prominent players in the market have adopted various strategies to garner maximum in vitro diagnostics market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Abbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., Danaher Corporation (Beckman Coulter, Inc.), F. Hoffmann-La Roche AG, Siemens AG, QIAGEN N.V., Sysmex Corporation, and Thermo Fisher Scientific, Inc.
Key Benefits For Stakeholders
This report entails a detailed quantitative analysis along with the current and future Europe in vitro diagnostics market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
The Europe in vitro diagnostics market forecast is studied from 2020 to 2027.
The Europe in vitro diagnostics market size and estimations are based on a comprehensive analysis of key developments in the industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key Europe in vitro diagnostics market players are enlisted to understand the competitive scenario of the market.
Key Market Segments
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Top winning strategies, 2019
3.4.Market Share Analysis, 2019
3.5.Porters five forces analysis
3.6.Market dynamics
3.6.1.Drivers
3.6.1.1.Increase in incidences of chronic and infectious diseases
3.6.1.2.Technological advancements in IVD
3.6.1.3.Rise in adoption of in vitro diagnostic testing
3.6.1.4.Rise in geriatric population
3.6.1.5.Increase in popularity of personalized medicine approach
3.6.2.Restraint
3.6.2.1.Unclear reimbursement policies
3.6.2.2.Stringent regulatory policies
3.6.3.Opportunity
3.6.3.1.Potential opportunities for outsourcing
3.6.4.Impact Analysis
3.7.COVID-19 Impact Analysis
CHAPTER 4:IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
4.1.Overview
4.1.1.Market size and forecast
4.2.Chemicals & Reagents
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by country
4.2.3.Market share analysis, by country
4.3.Instruments
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by country
4.3.3.Market share analysis, by country
4.4.Software & Services
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by country
4.4.3.Market share analysis, by country
CHAPTER 5:IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE
5.1.Overview
5.1.1.Market size and forecast
5.2.Immunodiagnostics
5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by country
5.2.3.Market share analysis, by country
5.2.4.Market size and forecast, by type
5.2.4.1.Enzyme-linked immunosorbent assay (ELISA)
5.2.4.1.1.Market size and forecast, by type
5.2.4.1.2.Chemiluminescence Immunoassay (CLIA)
5.2.4.1.2.1.Market size and forecast
5.2.4.1.3.Fluorescence immunoassay (FIA)
5.2.4.1.3.1.Market size and forecast
5.2.4.1.4.Colorimetric Immunoassay (CI)
5.2.4.1.4.1.Market size and forecast
5.2.4.2.Rapid Tests
5.2.4.2.1.Market size and forecast
5.2.4.3.Enzyme-linked immunospot (ELISPOT)
5.2.4.3.1.Market size and forecast
5.2.4.4.Radioimmunoassay (RIA)
5.2.4.4.1.Market size and forecast
5.2.4.5.Western blot
5.2.4.5.1.Market size and forecast
5.3.Hematology
5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by country
5.3.3.Market share analysis, by country
5.4.Molecular diagnostics
5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by country
5.4.3.Market share analysis, by country
5.4.4.Market size and forecast, by type
5.4.4.1.Polymerize chain reaction (PCR)
5.4.4.1.1.Market size and forecast
5.4.4.2.Isothermal Nucleic acid amplification technology (INAAT)
5.4.4.2.1.Market size and forecast
5.4.4.3.Hybridization
5.4.4.3.1.Market size and forecast
5.4.4.4.DNA diagnostics
5.4.4.4.1.Market size and forecast
5.4.4.5.Microarray
5.4.4.5.1.Market size and forecast
5.4.4.6.Others
5.4.4.6.1.Market size and forecast
5.5.Tissue diagnostics
5.5.1.Key market trends, growth factors, and opportunities
5.5.2.Market size and forecast, by country
5.5.3.Market share analysis, by country
5.6.Clinical chemistry
5.6.1.Key market trends, growth factors, and opportunities
5.6.2.Market size and forecast, by country
5.6.3.Market share analysis, by country
5.6.4.Market size and forecast, by type
5.6.4.1.Basic metabolic panel
5.6.4.1.1.Market size and forecast
5.6.4.2.Liver panel
5.6.4.2.1.Market size and forecast
5.6.4.3.Renal profile
5.6.4.3.1.Market size and forecast
5.6.4.4.Lipid profile
5.6.4.4.1.Market size and forecast
5.6.4.5.Thyroid function panel
5.6.4.5.1.Market size and forecast
5.6.4.6.Electrolyte panel
5.6.4.6.1.Market size and forecast
5.6.4.7.Specialty chemicals
5.6.4.7.1.Market size and forecast
5.7.Others
5.7.1.Key market trends, growth factors, and opportunities
5.7.2.Market size and forecast, by country
5.7.3.Market share analysis, by country
CHAPTER 6:IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
6.1.Overview
6.1.1.Market size and forecast
6.2.Infectious Diseases
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by country
6.2.3.Market share analysis, by country
6.3.Cancer
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by country
6.3.3.Market share analysis, by country
6.4.Cardiac diseases
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by country
6.4.3.Market share analysis, by country
6.5.Immune system disorders
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by country
6.5.3.Market share analysis, by country
6.6.Nephrological diseases
6.6.1.Key market trends, growth factors, and opportunities
6.6.2.Market size and forecast, by country
6.6.3.Market share analysis, by country
6.7.Gastrointestinal diseases
6.7.1.Key market trends, growth factors, and opportunities
6.7.2.Market size and forecast, by country
6.7.3.Market share analysis, by country
6.8.Others
6.8.1.Key market trends, growth factors, and opportunities
6.8.2.Market size and forecast, by country
6.8.3.Market share analysis, by country
CHAPTER 7:IN VITRO DIAGNOSTICS MARKET, BY END USER
7.1.Overview
7.1.1.Market size and forecast
7.2.Standalone Laboratories
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country
7.2.3.Market share analysis, by country
7.3.Hospitals
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country
7.3.3.Market share analysis, by country
7.4.Academic and medical schools
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country
7.4.3.Market share analysis, by country
7.5.Point-of-care testing
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country
7.5.3.Market share analysis, by country
7.6.Others
7.6.1.Key market trends, growth factors, and opportunities
7.6.2.Market size and forecast, by country
7.6.3.Market share analysis, by country
CHAPTER 8:IN VITRO DIAGNOSTICS MARKET, BY COUNTRY
8.1.Overview
8.1.1.Key market trends, growth factors, and opportunities
8.1.2.Market size and forecast, by country
8.1.2.1.Germany
8.1.2.2.Market size and forecast
8.1.2.2.1.Germany in vitro diagnostics market, by product & service
8.1.2.2.2.Germany In vitro diagnostics market, by technique
8.1.2.2.3.Germany In vitro diagnostics market, by application
8.1.2.2.4.Germany In vitro diagnostics market, by end user
8.1.2.3.France
8.1.2.4.Market size and forecast
8.1.2.4.1.France In vitro diagnostics market, by product & service
8.1.2.4.2.France In vitro diagnostics market, by technique
8.1.2.4.3.France In vitro diagnostics market, by application
8.1.2.4.4.France In vitro diagnostics market, by end user
8.1.2.5.UK
8.1.2.6.Market size and forecast
8.1.2.6.1.UK In vitro diagnostics market, by product & service
8.1.2.6.2.UK In vitro diagnostics market, by technique
8.1.2.6.3.UK In vitro diagnostics market, by application
8.1.2.6.4.UK In vitro diagnostics market, by end user
8.1.2.7.Italy
8.1.2.8.Market size and forecast
8.1.2.8.1.Italy in vitro diagnostics market, by product & service
8.1.2.8.2.Italy In vitro diagnostics market, by technique
8.1.2.8.3.Italy In vitro diagnostics market, by application
8.1.2.8.4.Italy In vitro diagnostics market, by end user
8.1.2.9.Spain
8.1.2.10.Market size and forecast
8.1.2.10.1.Spain In vitro diagnostics market, by product & service
8.1.2.10.2.Spain In vitro diagnostics market, by technique
8.1.2.10.3.Spain In vitro diagnostics market, by application
8.1.2.10.4.Spain In vitro diagnostics market, by end user
8.1.2.11.Rest of Europe
8.1.2.12.Market size and forecast
8.1.2.12.1.Rest of Europe In vitro diagnostics market, by product & service
8.1.2.12.2.Rest of Europe In vitro diagnostics market, by technique
8.1.2.12.3.Rest of Europe In vitro diagnostics market, by application
8.1.2.12.4.Rest of Europe In vitro diagnostics market, by end user
CHAPTER 9:COMPANY PROFILES
9.1.ABBOTT LABORATORIES
9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product and service portfolio
9.1.5.Business performance
9.1.6.Key strategic moves and developments
9.2.BECTON, DICKINSON AND COMPANY
9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product and service portfolio
9.2.5.Business performance
9.2.6.Key strategic moves and developments
9.3.BIOMÉRIEUX SA
9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product and service portfolio
9.3.5.Business performance
9.3.6.Key strategic moves and developments
9.4.BIO-RAD LABORATORIES, INC.
9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product and service portfolio
9.4.5.Business performance
9.4.6.Key strategic moves and developments
9.5.DANAHER CORPORATION (BECKMAN COULTER, INC.)
9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product and service portfolio
9.5.5.Business performance
9.5.6.Key strategic moves and developments
9.6.F. HOFFMANN-LA ROCHE AG.
9.6.1.Company snapshot
9.6.2.Operating business segments
9.6.3.Product and service portfolio
9.6.4.Business performance
9.6.5.Key strategic moves and developments
9.7.QIAGEN N.V.
9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product and service portfolio
9.7.5.Business performance
9.7.6.Key strategic moves and developments
9.8.SIEMENS AG (SIEMENS HEALTHINEERS)
9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance
9.8.6.Key strategic moves and developments
9.9.SYSMEX CORPORATION
9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product and service portfolio
9.9.5.Business performance
9.10.THERMO FISHER SCIENTIFIC, INC.
9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product and service portfolio
9.10.5.Business performance
9.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.ESTIMATED GERIATRIC POPULATION IN EUROPEAN COUNTRIES, 2018
TABLE 02.TYPES OF IN VITRO DIAGNOSTIC PRODUCTS AVAILABLE FOR COVID-19 DIAGNOSIS
TABLE 03.IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027 ($MILLION)
TABLE 04.IN VITRO DIAGNOSTICS MARKET FOR CHEMICAL & REAGENTS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 05.IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 06.IN VITRO DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2019–2027 ($MILLION)
TABLE 07.IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027 ($MILLION)
TABLE 08.IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 09.IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY TYPE, 2019–2027 ($MILLION)
TABLE 10.IN VITRO DIAGNOSTICS MARKET FOR ELISA, BY TYPE, 2019–2027 ($MILLION)
TABLE 11.IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 12.IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 13.MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 14.IN VITRO DIAGNOSTICS MARKET FOR TISSUE DIAGNOSTICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 15.IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 16.CLINICAL CHEMISTRY MARKET, BY TYPE, 2019–2027 ($MILLION)
TABLE 17.IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 18.IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 19.IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,2019–2027 ($MILLION)
TABLE 20.IN VITRO DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY,2019–2027 ($MILLION)
TABLE 21.IN VITRO DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY COUNTRY,2019–2027 ($MILLION)
TABLE 22.IN VITRO DIAGNOSTICS MARKET FOR IMMUNE SYSTEM DISORDERS, BY COUNTRY,2019–2027 ($MILLION)
TABLE 23.IN VITRO DIAGNOSTICS MARKET FOR NEPROLOGICAL DISEASES, BY COUNTRY,2019–2027 ($MILLION)
TABLE 24.IN VITRO DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY,2019–2027 ($MILLION)
TABLE 25.IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY,2019–2027 ($MILLION)
TABLE 26.IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 27.IN VITRO DIAGNOSTICS MARKET FOR STANDALONE LABORATORIES, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 28.IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 29.IN VITRO DIAGNOSTICS MARKET FOR ACADEMICS & MEDICAL SCHOOLS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 30.IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 31.IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 32.EUROPE IN VITRO DIAGNOSTICS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 33.GERMANY IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027
TABLE 34.GERMANY IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027
TABLE 35.GERMANY IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027
TABLE 36.GERMANY IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027
TABLE 37.FRANCE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027
TABLE 38.FRANCE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027
TABLE 39.FRANCE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027
TABLE 40.FRANCE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027
TABLE 41.UK IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027
TABLE 42.UK IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027
TABLE 43.UK IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027
TABLE 44.UK IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027
TABLE 45.ITALY IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027
TABLE 46.ITALY IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027
TABLE 47.ITALY IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027
TABLE 48.ITALY IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027
TABLE 49.SPAIN IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027
TABLE 50.SPAIN IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027
TABLE 51.SPAIN IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027
TABLE 52.SPAIN IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027
TABLE 53.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2019–2027
TABLE 54.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2019–2027
TABLE 55.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY APPLICATION, 2019–2027
TABLE 56.REST OF EUROPE IN VITRO DIAGNOSTICS MARKET, BY END USER, 2019–2027
TABLE 57.ABBOTT: COMPANY SNAPSHOT
TABLE 58.ABBOTT: OPERATING SEGMENTS
TABLE 59.ABBOTT: PRODUCT AND SERVICE PORTFOLIO
TABLE 60.BD : COMPANY SNAPSHOT
TABLE 61.BD : OPERATING SEGMENTS
TABLE 62.BD: PRODUCT AND SERVICE PORTFOLIO
TABLE 63.BIOMÉRIEUX: COMPANY SNAPSHOT
TABLE 64.BIOMÉRIEUX: OPERATING SEGMENTS
TABLE 65.BIOMÉRIEUX: PRODUCT AND SERVICE PORTFOLIO
TABLE 66.BIO-RAD: COMPANY SNAPSHOT
TABLE 67.BIO-RAD: OPERATING SEGMENTS
TABLE 68.BIO-RAD: PRODUCT AND SERVICE PORTFOLIO
TABLE 69.DANAHER: COMPANY SNAPSHOT
TABLE 70.DANAHER: OPERATING SEGMENTS
TABLE 71.DANAHER: PRODUCT AND SERVICE PORTFOLIO
TABLE 72.ROCHE: COMPANY SNAPSHOT
TABLE 73.ROCHE: OPERATING SEGMENTS
TABLE 74.ROCHE: PRODUCT AND SERVICE PORTFOLIO
TABLE 75.QIAGEN: COMPANY SNAPSHOT
TABLE 76.QIAGEN: OPERATING SEGMENTS
TABLE 77.QIAGEN: PRODUCT AND SERVICE PORTFOLIO
TABLE 78.SIEMENS: COMPANY SNAPSHOT
TABLE 79.SIEMENS: OPERATING SEGMENTS
TABLE 80.SIEMENS: PRODUCT PORTFOLIO
TABLE 81.SYSMEX: COMPANY SNAPSHOT
TABLE 82.SYSMEX: OPERATING SEGMENTS
TABLE 83.SYSMEX: PRODUCT AND SERVICE PORTFOLIO
TABLE 84.THERMO FISHER: COMPANY SNAPSHOT
TABLE 85.THERMO FISHER: OPERATING SEGMENTS
TABLE 86.THERMO FISHER SCIENTIFIC: PRODUCT AND SERVICE PORTFOLIO
LIST OF FIGURES
FIGURE 01.IN-VITRO DIAGNOSTICS MARKET SEGMENTATION
FIGURE 02.TECHNIQUE MARKET SUB-SEGMENTATION
FIGURE 03.TOP INVESTMENT POCKETS
FIGURE 04.TOP WINNING STRATEGIES, 2017–2020
FIGURE 05.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020
FIGURE 06.TOP WINNING STRATEGIES: BY YEAR, 2017–2020
FIGURE 07.MARKET SHARE ANALYSIS, 2019
FIGURE 08.BARGANING POWER OF BUYERS
FIGURE 09.BARGANING POWER OF SUPPLIERS
FIGURE 10.THREAT OF SUBSTITUTIONS
FIGURE 11.THREAT OF NEW ENTRANTS
FIGURE 12.MODERATE COMPETITIVE RIVALRY
FIGURE 13.IMPACT ANALYSIS, IN-VITRO DIAGNOSTICS MARKET
FIGURE 14.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CHEMICALS & REAGENTS, BY COUNTRY, 2019 & 2027
FIGURE 15.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2019 & 2027
FIGURE 16.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2019 & 2027
FIGURE 17.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2019 & 2027
FIGURE 18.IMMUNODIAGNOSTICS MARKET FOR ENZYME LINKED IMMUNOSORBENT ASSAY, 2019–2027 ($MILLION)
FIGURE 19.IMMUNODIAGNOSTICS MARKET FOR RAPID TESTS, 2019–2027 ($MILLION)
FIGURE 20.IMMUNODIAGNOSTICS MARKET FOR ENZYME-LINKED IMMUNOSPOT (ELISPOT), 2019–2027 ($MILLION)
FIGURE 21.IMMUNODIAGNOSTICS MARKET FOR RADIOIMMUNOASSAY (RIA), 2019–2027 ($MILLION)
FIGURE 22.IMMUNODIAGNOSTICS MARKET FOR WESTERN BLOT, 2019–2027 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2019 & 2027
FIGURE 24.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2019 & 2027
FIGURE 25.MOLECULAR DIAGNOSTICS MARKET FOR POLYMERIZE CHAIN REACTION (PCR), 2019–2027 ($MILLION)
FIGURE 26.MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), 2019–2027 ($MILLION)
FIGURE 27.MOLECULAR DIAGNOSTICS MARKET FOR HYBRIDIZATION, 2019–2027 ($MILLION)
FIGURE 28.MOLECULAR DIAGNOSTICS MARKET FOR DNA DIAGNOSTICS, 2019–2027 ($MILLION)
FIGURE 29.MOLECULAR DIAGNOSTICS MARKET FOR MICROARRAY, 2019–2027 ($MILLION)
FIGURE 30.MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, 2019–2027 ($MILLION)
FIGURE 31.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR TISSUE DIAGNOSTICS, BY COUNTRY, 2019 & 2027
FIGURE 32.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2019 & 2027
FIGURE 33.CLINICAL CHEMISTRY MARKET FOR BASIC METABOLIC PANEL, 2019–2027 ($MILLION)
FIGURE 34.CLINICAL CHEMISTRY MARKET FOR LIVER PANEL, 2019–2027 ($MILLION)
FIGURE 35.CLINICAL CHEMISTRY MARKET FOR RENAL PROFILE, 2019–2027 ($MILLION)
FIGURE 36.CLINICAL CHEMISTRY MARKET FOR LIPID PROFILE, 2019–2027 ($MILLION)
FIGURE 37.CLINICAL CHEMISTRY MARKET FOR THYROID FUNCTION PANEL, 2019–2027 ($MILLION)
FIGURE 38.CLINICAL CHEMISTRY MARKET FOR ELECTROLYTE PANEL, 2019–2027 ($MILLION)
FIGURE 39.CLINICAL CHEMISTRY MARKET FOR SPECIALTY CHEMICALS, 2019–2027 ($MILLION)
FIGURE 40.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027
FIGURE 41.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019 & 2027
FIGURE 42.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2019 & 2027
FIGURE 43.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR CARDIAC DISEASES, BY COUNTRY, 2019 & 2027
FIGURE 44.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR IMMUNE SYSTEM DISORDERS, BY COUNTRY, 2019 & 2027
FIGURE 45.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2019 & 2027
FIGURE 46.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019 & 2027
FIGURE 47.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019 & 2027
FIGURE 48.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR STANDALONE LABORATORIES, BY COUNTRY, 2019 & 2027
FIGURE 49.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2019 & 2027
FIGURE 50.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR ACADEMICS & MEDICAL SCHOOLS, BY COUNTRY, 2019 & 2027
FIGURE 51.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2019 & 2027
FIGURE 52.COMPARATIVE ANALYSIS OF IN VITRO DIAGNOSTICS MARKET FOR POINT-OF-CARE TESTING, BY COUNTRY, 2019 & 2027
FIGURE 53.GERMANY IN-VITRO DIAGNOSTICS MARKET, 2019–2027 ($MILLION)
FIGURE 54.FRANCE IN-VITRO DIAGNOSTICS MARKET, 2019–2027 ($MILLION)
FIGURE 55.UK. IN-VITRO DIAGNOSTICS MARKET, 2019–2027 ($MILLION)
FIGURE 56.ITALY IN-VITRO DIAGNOSTICS MARKET, 2019–2027 ($MILLION)
FIGURE 57.SPAIN IN-VITRO DIAGNOSTICS MARKET, 2019–2027 ($MILLION)
FIGURE 58.REST OF EUROPE IN-VITRO DIAGNOSTICS MARKET, 2019–2027 ($MILLION)
FIGURE 59.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 60.ABBOTT: NET SALES SHARE, BY OPERATING SEGMENT, 2019 (%)
FIGURE 61.ABBOTT: NET SALES SHARE, BY REGION, 2019 (%)
FIGURE 62.BD: REVENUE, 2017–2019 ($MILLION)
FIGURE 63.BD: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 64.BD: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 65.BIOMÉRIEUX: NET SALES, 2016–2018 ($MILLION)
FIGURE 66.BIOMÉRIEUX: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 67.BIOMÉRIEUX: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 68.BIO-RAD: NET SALES, 2017–2019 ($MILLION)
FIGURE 69.BIO-RAD: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 70.BIO-RAD: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 71.DANAHER: NET SALES, 2017–2019 ($MILLION)
FIGURE 72.DANAHER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 73.DANAHER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 74.ROCHE: NET SALES, 2017–2019 ($MILLION)
FIGURE 75.ROCHE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 76.QIAGEN: NET SALES, 2017–2019 ($MILLION)
FIGURE 77.QIAGEN: REVENUE SHARE, BY PRODUCT AND SERVICE, 2019 (%)
FIGURE 78.QIAGEN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 79.NET SALES, 2017–2019 ($MILLION)
FIGURE 80.SIEMENS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 81.SIEMENS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 82.SYSMEX: REVENUE, 2017–2019 ($MILLION)
FIGURE 83.SYSMEX: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 84.SYSMEX: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 85.THERMO FISHER SCIENTIFIC: REVENUE, 2016–2018 ($MILLION)
FIGURE 86.THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 87.THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY REGION, 2018 (%)
In accordance to several interviews conducted, the utilization of in vitro diagnostic techniques is likely to witness a significant rise with increase in diseases diagnosis. The Europe in vitro diagnostics market has piqued the interest of the healthcare industry, owing to its high accuracy and precise techniques, coupled with wide range of applications across various medical conditions, such as oncology, sexually transmitted diseases (STDs), chronic diseases, genetic testing, and infectious diseases. Furthermore, there have been remarkable advancements and some major developments in this market, such as devices with more throughput and accurate results. In addition, increase in chronic & infectious diseases, use of automated instruments, and rise in awareness regarding early diagnosis of medical condition for better treatment also fuels the growth of market.
According to the perspectives of CXOs of leading companies in the market, personalized medicine approach, cost-effective treatment, and technological advancements are some of the major factors that drive the Europe in vitro diagnostics market. However, lack of reimbursement rules and stringent regulatory policies hamper the market growth. Presently, standalone laboratories are the largest end users of IVD techniques in Europe followed by hospitals.
A. The total market value of Europe in vitro diagnostics market is $13,824.81 million in 2019.
A. The forcast period for Europe in vitro diagnostics market is 2020 to 2027
A. The market value of Europe in vitro diagnostics market in 2020 is $13,468.55 million.
A. The base year is 2019 in Europe in vitro diagnostics market
A. Top companies such as, F. Hoffmann-La Roche AG, Danaher Corporation (Beckman Coulter, Inc.), Thermo Fisher Scientific, Inc., Abbott Laboratories, and Dickinson and Company held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
A. Instruments segment is the most influencing segment as these devices are fully automated instruments and these simplify a task and provide more accurate and reliable results.
A. The major factor that fuels the growth of the global Europe in vitro diagnostics market includes rise in prevalence of various chronic diseases such as diabetes, cancer and others which require the use of in vitro diagnostics
A. UK has the highest growth rate in the market with a CAGR of 6.8%. This is due to surge in prevalence of seasonal flu and rise in adoption of in vitro diagnostic testing in the country.
A. In vitro diagnostics is defined as medical devices which are used by laboratories to perform diagnostic tests inside a laboratory.
A. In vitro diagnostics (IVD) are used to examine specimens such as blood, urine, stool, tissues, and other body fluids, which are derived from human body to detect diseases, conditions, and infections.
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
